Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

By M. Keating, I. Flinn, V. Jain, J. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker and 1 more. Blood, 2002

1,023 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The PI3K/AKT Pathway as a Target for Cancer Treatment. (2016, methodology): “F or p er so na l u se o nl y. Table 1 Select PI3K inhibitors in clinical development Drug target Drug Source Phase of development Tumor types Pan-PI3K Buparlisib (BKM120) Novartis Phase 3 Advanced solid cancers, NSCLC, endometrial, prostate, breast, colorectal, pancreatic, renal cell, GIST, melanom”
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance (2003, background): “In CLL, a disease in which the cells have low CD20 levels and a low response rate to standard dose and schedule rituximab (375mg/m2 weekly 4), higher and repeated doses did lead to higher response rates, although these tend to be short lived (Byrd et al., 2001; Keating et al., 2002b).”
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (2015, neutral): “Chromosome 11q deletion 13/49 (27) 15/53 (28) 28/102 (27)”